Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fosfomycin + imipenem
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Fosfomycin + imipenem is an antibiotic combination therapy that demonstrates synergistic effects against various resistant bacterial pathogens. Fosfomycin inhibits bacterial cell wall synthesis by binding to UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), preventing peptidoglycan formation, while imipenem targets penicillin-binding proteins. This combination has shown particular efficacy against methicillin-resistant Staphylococcus aureus (MRSA), including glycopeptide-intermediate and daptomycin-nonsusceptible strains, as well as multidrug-resistant gram-negative bacteria like Acinetobacter baumannii. It has been studied as salvage therapy for serious infections.
02
Targets
PBP (Penicillin-binding protein family)MurA (UDP-N-acetylglucosamine 1-carboxyvinyltransferase)
Beyond the preview
Go deeper on fosfomycin + imipenem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fosfomycin + imipenem.